主页 > 医学前沿 >
【drug-news】终止转移性肾癌进程的新药(sina采用
03/01/07 -- Research has shown the efficacy of a pharmaceutical drug known as sunitinib which halts progress of metastatic kidney cancer. The work was published recently in the prestigious international medical journal, The New England Journal of Medicine and involved medical co-researchers from the Oncology Department of the University Hospital of Navarra, in collaboration with the Clinical Trials Area of the same Department.
To date the usual treatment for kidney cancer of a metastatic nature has been based solely on immunotherapy. In phase III of the research sunitinib was compared with interferon (a type of immunotherapy) in 750 patients with metastatic kidney cancer and it was shown that sunitinib is more efficient in halting the progress of the disease. 101 medical centres from all over the world took part in the research.
Given the short period of follow-up in the research, the effect of the treatment on survival rates could not be corroborated. Although, in general, the treatment is well tolerated, certain side effects can occur and have to be taken into consideration - hypothyroidism, high blood pressure and fatigue.
Metastatic kidney cancer is one of the cancer pathologies the treatment of which has made least progress in recent years. The usual treatment with immunotherapy had not shown clearly positive results in many patients. Sunitinib is one of the few pharmaceutical drugs that provide clear improvements in this type of cancer. The mechanism of functioning of sunitinib is in blocking the generation of new blood vessels. Tumours, in order to grow, need to develop blood vessels and this pharmaceutical drug impedes their growth, blocking a factor known as VEGF, and other similar ones, which stimulate vascular growth. The use of sunitinib in Spain is to be approved shortly for the treatment of kidney cancer with metastasis although, at the University Hospital, it has been employed with over 40 patients for the last two years, using clinical trials.
Source: Clínica Universitaria. Universidad de Navarra
http://www.bio.com/newsfeatures/newsfeatures_research.jhtml?cid=26600025 A New Pharmaceutical Drug that Halts Progress of Metastatic Kidney Cancer
终止转移性肾癌进程的新药
03/01/07 -- Research has shown the efficacy of a pharmaceutical drug known as sunitinib which halts progress of metastatic kidney cancer. The work was published recently in the prestigious international medical journal, The New England Journal of Medicine and involved medical co-researchers from the Oncology Department of the University Hospital of Navarra, in collaboration with the Clinical Trials Area of the same Department.
2007年3月1日－－研究发现舒尼替尼(sunitinib)能有效阻止转移性肾癌进程。该项研究最近已在世界著名医学刊物《新英格兰医学杂志》发行，由那瓦尔大学医院肿瘤系研究者和该系临床试验基地共同合作完成。
To date the usual treatment for kidney cancer of a metastatic nature has been based solely on immunotherapy. In phase III of the research sunitinib was compared with interferon (a type of immunotherapy) in 750 patients with metastatic kidney cancer and it was shown that sunitinib is more efficient in halting the progress of the disease. 101 medical centres from all over the world took part in the research.
目前转移性肾癌常用治疗措施主要还是单纯免疫抑制剂治疗。该项实验III期临床试验中对比分析了750例转移性肾癌患者接受舒尼替尼和干扰素(免疫疗法)的治疗效果，结果显示舒尼替尼治疗组更能有效阻止疾病进展。全球共有101个医疗中心参与了该研究。
Given the short period of follow-up in the research, the effect of the treatment on survival rates could not be corroborated. Although, in general, the treatment is well tolerated, certain side effects can occur and have to be taken into consideration - hypothyroidism, high blood pressure and fatigue.
研究跟踪报道接受舒尼替尼短期治疗后尚未发现能提高患者生存率。大体来说，患者都能耐受给项治疗，也存在某些副作用，需要注意的是－－甲状腺功能减退、高血压以及疲劳。
Metastatic kidney cancer is one of the cancer pathologies the treatment of which has made least progress in recent years. The usual treatment with immunotherapy had not shown clearly positive results in many patients. Sunitinib is one of the few pharmaceutical drugs that provide clear improvements in this type of cancer. The mechanism of
functioning of sunitinib is in blocking the generation of new blood vessels. Tumours, in order to grow, need to develop blood vessels and this pharmaceutical drug impedes their growth, blocking a factor known as VEGF, and other similar ones, which stimulate vascular growth. The use of sunitinib in Spain is to be approved shortly for the treatment of kidney cancer with metastasis although, at the University Hospital, it has been employed with over 40 patients for the last two years, using clinical trials.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-06-23 19:12
医学,生命科学网